Key Highlights

  • Pre-market price of USD 1.60 on November 4, 2026, up USD 0.1700 from the Tuesday close.
  • First half 2026 net loss narrowed to about USD 295,000 from about USD 2.4 million.
  • Second quarter 2026 Revenue was about USD 706,000, compared with about USD 683,000 a year earlier.
  • Cash stood at about USD 1.3 million at June 30, 2026, with a further USD 938,000 raised in September 2026.
  • Nasdaq resumed trading on October 7, 2026 under a one-year panel monitor.

Price Action Before the Open (up USD 0.1700, 11.89%)

SCWorx (NASDAQ:WORX) was up 11.89% at USD 1.60 in pre-market trading on November 4, 2026, a gain of USD 0.1700 from the Tuesday, November 3 close of USD 1.43 (calculated). The stock was quoted at USD 2.01 on October 15, 2026, according to the company's registration statement, so shares remain below that level even after the rise.

No company announcement dated November 2 to November 4, 2026 was identified, so no catalyst can be confirmed. The latest news flow includes the October 19, 2026 announcement of a new healthcare customer. A stock with fewer than 1 million shares outstanding can move sharply on small order flow.

Business and Recent Updates

SCWorx is a Delaware company based in Middleton, Massachusetts that sells healthcare IT software and services. Its tools normalize, organize and integrate hospital data across Supply chain, clinical and billing systems, typically under software-as-a-service contracts lasting one to five years.

On October 19, 2026 the company announced an agreement with an independent, community-owned healthcare system serving New Mexico, Arizona, Colorado and Utah, covering supply chain data management. The contract value and term were not disclosed. Earlier wins include a two-year agreement with a large Massachusetts health network.

In a press release dated October 7, 2026, the company said it is developing an AI-enabled data management model that combines commercial large language models with its healthcare data Assets and human quality assurance. Chief executive Tim Hannibal said, "Our goal now is execution."

Results, Listing Status and Risks

For the second quarter of 2026, revenue was about USD 706,000 and Gross Profit rose about 83% to about USD 330,000. The net loss was about USD 121,000, compared with about USD 1.9 million a year earlier, helped by the end of roughly USD 1.7 million in first half interest and Debt discount amortization tied to convertible notes that are no longer outstanding. First half revenue was about USD 1.45 million, and cash used in operations fell to about USD 258,000 from about USD 1.1 million.

The listing path was uneven. Trading was suspended on April 14, 2026, a Nasdaq panel issued a delisting decision on September 17, 2026, and on October 2, 2026 the panel reversed that decision, citing compliance with listing requirements. Trading resumed on October 7, 2026. The company carried out a 1-for-15 reverse split in April and a 1-for-12 reverse split on August 3, 2026, and a panel monitor runs through October 2, 2027.

The shares are a penny stock, so Volatility and thin Liquidity are significant. On October 16, 2026 the company filed a resale registration statement covering warrants that could bring in up to about USD 32.5 million if exercised for cash. Warrant exercises or resales could dilute holders or weigh on the price. The company also said it cannot assure that it will maintain compliance.

What to Watch Next

Third quarter 2026 results and the company's monthly reporting to Nasdaq will be the next data points, along with any further customer announcements showing Recurring Revenue growth. Whether the stock stays above the USD 1.00 minimum bid price also matters.